Page 73 - Eceptor News Today

The nanomaterial graphene oxide-;which is used in everything from electronics to sensors for biomolecules-;can indirectly affect the immune system via the gut microbiome, as shown in a new study on zebrafish by researchers at Karolinska Institutet in Sweden.

MIT researchers have identified molecules found in mucus that can block cholera infection by interfering with the genes that cause the microbe to switch into a harmful state.

Researchers apply computational approaches to study the binding mechanisms of the SARS-CoV-2 and SARS-CoV spike proteins to the ACE2 receptor.

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Researchers compared the efficiency of bioengineered soluble ACE-2 concerning brain protection during COVID-19.

A new study in the journal Nature Communications reveals how a viral toxin produced by the SARS-CoV-2 virus may contribute to severe COVID-19 infections.

An inflammatory molecule called LIGHT, appears to be the cause of life-threatening airway damage in patients with severe asthma.

Using new machine learning techniques, researchers at UC San Francisco (UCSF), in collaboration with a team at IBM Research, have developed a virtual molecular library of thousands of "command sentences" for cells, based on combinations of "words" that guided engineered immune cells to seek out and tirelessly kill cancer cells.

Researchers assessed the association between farnesoid X receptor (FXR) inhibition and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.